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Combined PDK1 and CHK1 inhibition is required to kill
glioblastoma stem-like cells in vitro and in vivo
M Signore*,1, F Pelacchi1, S di Martino2, D Runci1, M Biffoni1, S Giannetti3, L Morgante3, M De Majo1, EF Petricoin4, L Stancato5,
LM Larocca6, R De Maria2, R Pallini7,8 and L Ricci-Vitiani*,1,8
Glioblastoma (GBM) is the most common and deadly adult brain tumor. Despite aggressive surgery, radiation, and
chemotherapy, the life expectancy of patients diagnosed with GBM isB14 months. The extremely aggressive nature of GBM
results from glioblastoma stem-like cells (GSCs) that sustain GBM growth, survive intensive chemotherapy, and give rise to
tumor recurrence. There is accumulating evidence revealing that GSC resilience is because of concomitant activation of multiple
survival pathways. In order to decode the signal transduction networks responsible for the malignant properties of GSCs, we
analyzed a collection of GSC lines using a dual, but complementary, experimental approach, that is, reverse-phase protein
microarrays (RPPMs) and kinase inhibitor library screening. We treated GSCs in vitro with clinically relevant concentrations of
temozolomide (TMZ) and performed RPPM to detect changes in phosphorylation patterns that could be associated with
resistance. In addition, we screened GSCs in vitro with a library of protein and lipid kinase inhibitors to identify specific targets
involved in GSC survival and proliferation. We show that GSCs are relatively insensitive to TMZ treatment in terms of pathway
activation and, although displaying heterogeneous individual phospho-proteomic profiles, most GSCs are resistant to specific
inhibition of the major signaling pathways involved in cell survival and proliferation. However, simultaneous multipathway
inhibition by the staurosporin derivative UCN-01 results in remarkable inhibition of GSC growth in vitro. The activity of UCN-01 on
GSCs was confirmed in two in vivo models of GBM growth. Finally, we used RPPM to study the molecular and functional effects
of UCN-01 and demonstrated that the sensitivity to UCN-01 correlates with activation of survival signals mediated by PDK1 and
the DNA damage response initiated by CHK1. Taken together, our results suggest that a combined inhibition of PDK1 and CHK1
represents a potentially effective therapeutic approach to reduce the growth of human GBM.
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Glioblastoma multiforme (GBM) is the second most common
brain tumor in people aged from 55 to 84 years.1 Current
standard therapy, includingmaximal safe resection followed by
radiotherapy in combination with temozolomide (TMZ), does
not yield definitive effects and a majority of patients succumb
to the disease within 2 years after diagnosis.2 One of the major
hurdles to surgical resection and the major cause of relapse is
the invasive nature of GBM and its intrinsic resistance to
therapy.3,4 Such tumorigenic properties have been ascribed to
a rare fraction of self-renewing, multipotent tumor-initiating
cells, GBM stem-like cells (GSCs), responsible for tumor
progression, maintenance, and recurrence.5–7 GSCs play a
critical role in both invasiveness and chemo- and radio-
resistance of GBM.8,9 Moreover, GSCs may sustain tumor
angiogenesis by vascular differentiation.10,11 These character-
istics make their elimination an extremely difficult task.
The recent characterization of the human cancer
genome (Cancer Genome Atlas Research Network, 2008;
http://cancergenome.nih.gov/)12 and transcriptome13,14 of
GBM has provided a high-resolution picture that has revealed
the major gene alterations that may drive disease pathogen-
esis and biology. The commonly altered genes includeEGF-R
(B40%), PTEN (37%), PIK3CA (13%), PIK3R1 (8%), and
PDGFRA (8%). Over 80% of GBMs have an acquired
alteration in the RTK/PI3K/AKT pathway with B40% of
tumors having some alteration in EGF-R. These comprehen-
sive data sets reveal GBM as a heterogeneous collection of
distinct diseases with multiple dependencies both within and
across each particular subtype. Despite apparent single
pathway perturbations found in GBM, specific target drugs,
including those that target AKT/mTOR, did not show clinical
efficacy.15 DNA alterations may not translate to protein
derangements and often times the DNA–protein correlations
are weak. Therefore, to further dissect GBM signaling path-
ways and to find appropriate clinical targets to be exploited for
drug discovery, several investigators have attempted to
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characterize GSCs at the molecular and functional levels.
EGF-R signaling is known to substantially contribute to GBM
malignancy and, using amass spectrometry-based approach,
Kozuka-Hata et al.16 performed a comprehensive analysis of
the phospho-proteome of GSCs in response to EGF stimula-
tion. They identified multiple signaling pathway perturbations
with calcium-dependent protein kinase C (PKC), AKT, and
CHK1/2 significantly modulated by EGF. Growing evidence
reveals that GSCs display extensive multiple kinase activa-
tion,17 and therefore sustained activation of multiple non-
overlapping signaling pathways could be a major issue in
therapeutic intervention.18–20 Recent advances in the devel-
opment of small molecules and the broad spectrum of activity
exhibited by several FDA-approved drugs21 may help to
identify novel small molecule therapies for GBM.
Commercially available immortalized cancer cell lines
cannot account for the genetic diversity between patients or
for the heterogeneity of tumor cells. Novel approaches
directed at eradicating GBM could be greatly strengthened
by the use of patient-derived GSCs that more closely mimic
primary GBM. In the present work, we analyzed a diverse
collection of GSC lines22 by combining a powerful phospho-
proteomic platform (reverse-phase protein microarrays,
RPPMs), with small molecule kinase inhibitor library screen-
ing, aimed at identifying and interrogating signaling pathways
involved in GSC resistance to therapy.
Results
GSCs are resistant to TMZ and their pathway activation
pattern is not influenced by treatment. TMZ is the current
standard of care for patients with GBM; however, only a
minority of patients survives for 43 years. We successfully
isolated and characterized stem-like cell lines from several
GBM patients. These cells exhibit tumorigenic properties
in vitro and in vivo and represent a powerful tool for molecular
investigation of GBM.3,22,23 Most of the GSCs used in the
present study are resistant in vitro to clinically relevant
concentrations of TMZ,24 irrespective of their MGMT or
PTEN status (Figure 1a and Supplementary Table S1), as
previously reported.3 Among the available technologies in
proteomics, RPPM represents one of the most flexible and
robust technology,25,26 providing quantitative broad-scale
measurement of hundreds of phosphoproteins, even low
abundance signaling molecules that are below the detection
limits of mass spectrometry. To understand whether TMZ
resistance correlated with specific signal transduction path-
way activation, we performed RPPM analysis on lysates from
GSCs treated for 72 h with TMZ. Incubation time was
selected after preliminary time course evaluation (Supple-
mentary Figure S1). Hierarchical clustering of proteins
involved in survival and proliferation showed that pathway
activation mainly groups by GSC line rather than by
treatment (Figure 1b). GSCs do not show major changes in
their pathway activation profile and most GSCs display diffe-
rential activation of nodes in the same pathways, pointing to
a molecular differentiation based on rearrangement of the
signaling network rather than differential activation of parallel
pathways (Supplementary Table S2).
Small molecule kinase inhibitor library screening
identifies potential therapeutic targets. Our phospho-
proteomic-based pathway activation mapping analysis sug-
gested that the intrinsic resistance of GSCs to cytotoxic
drugs is dependent upon constitutively active pro-survival
pathways and confirms previous findings reported by other
investigators.17–20 Therefore, we decided to treat GSCs with a
commercially available small molecule kinase inhibitor library
composed of 80 different compounds targeting a multitude of
human protein or lipid kinases (Supplementary Table S3). The
two GSC lines assayed displayed marked resistance to most
of the compounds tested, whereas inhibition of PKC (rottlerin
and Ro 31–8220) or ERK2/adenosine kinase (5-iodotuberci-
din), PDGF-R (tyrphostin 9), and EGF-R (erbstatin analog)
inhibitors yielded significant antiproliferative results
(Figure 2a). Our functional data derived from in vitro kinase
inhibition confirm the existence of strong survival signals in
GSCs that confer resistance to targeted inhibition.
As the specificity of kinase inhibitors can vary with
compound concentration (i.e., increasing concentration often
yields increasing off-target effects), we performed titration
assays to better understand the specificity of the compounds
found effective in the library screening at relatively high
concentration (Figure 2b). Most of the compounds were
inactive at submicromolar concentrations, as shown by
markedly high EC50 values for all cell lines. Thus, we tested
compounds with analog target specificity in order to verify
previous results (Figures 2b–d). These analog compounds
included a preclinical ERK inhibitor and two compounds
already in use in the clinics (gefitinib and sorafenib, Figure 2c)
and, as two out of the five positive hits had PKC as the primary
target, we used an additional set of inhibitors against this
kinase (Figure 2d). One of the PKC inhibitors, the staur-
osporine derivative UCN-01 (7-hydroxy-staurosporine), was
the most effective antiproliferative agent, yielding a range of
sensitivity across the GSC lines. We classified GSCs into
three sensitivity groups, that is, low, medium, and high, based
on the relative efficacy of UCN-01. The commercial cell line
T98G was more sensitive than any GSC, whereas U87MG
was included in the low-sensitivity group (Table 1). Normal
neural stem cells27 were less sensitive than GSCs and
sensitivity to UCN-01 markedly increased after in vitro
differentiation (Supplementary Figure S2). To confirm the
ability of UCN-01 to induce cell death, we evaluated DNA
content in GSCs treated with the compound. The increase in
the pre-G0 peak in the treated samples as compared with
control correlated with the sensitivity displayed byGSCs in the
ATP-based assay (Supplementary Figures S3a and b).
Microscopic examination of GSCs treated with UCN-01
confirmed the presence of morphological (AO/PI) and func-
tional (TUNEL) signatures of apoptosis mainly in the highly
sensitive lines (Supplementary Figure S3c).
UCN-01 cytotoxic effect is mediated by PDK1 and CHK1
inhibition. UCN-01 is a potent inhibitor of CHK1 (Ki¼ 5.6
nM), 30-phosphoinositide-dependent protein kinase-1
(PDK1; IC50¼ 5.0 nM), PKCb (IC50¼ 10 nM), and CDKs (Ki:
CDK1 and CDC2 95nM, CDK2 30nM, and CDK4 3.6 mM),
and other PKC isoforms (IC50o1 mM) are inhibited with a
lower potency.28–31 Despite the fact that both staurosporine
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Figure 1 TMZ treatment and RPPM analysis of GSCs. (a) A collection of GSCs and two commercially available GBM cell lines have been treated with increasing doses of
TMZ and viability was measured at 72 h. Data are represented as mean±S.E.M. from at least three independent experiments. (b) Hierarchical clustering of RPPM data (mean
of three technical replicates) obtained by assaying a panel of antibodies mainly directed against components of the EGF-R and PI3-K/AKT/mTOR pathways on protein lysates
of selected GSC lines treated either with vehicle (DMSO) or with 50 mM TMZ for either 12 or 72 h. Colored clusters were selected by cutting the dendrogram at the height
indicated in the upper-right hierarchy plot. A summary of the phosphoproteins present in each cluster is available as Supplementary Table S2
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Figure 2 Kinase inhibitor library screening and titration assays of positive hits and analogs in GSCs. (a) Point chart of the viability of two GSCs and two commercial GBM
cell lines treated with the kinase inhibitor library each compound at 5 mM for 72 h. Normalized viability of each cell line is plotted as mean±S.D. from three independent
experiments. Horizontal dashed lines represent reference lines for 100% (dark green) and 50% (red) viability. (b) Parallel plots of fitted 4PL curves and correspondent
hierarchical clustering maps of pEC50 values (see Materials and Methods section for details) derived from titration curves of GSCs treated for 72 h with positive hits from the
library screening and (c and d) analog compounds. Fitting was performed on individual dose-response curves obtained from three independent experiments
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and UCN-01 are relatively nonspecific inhibitors, the activity
of UCN-01 is significantly different from that of stauro-
sporine.29,32 In order to investigate which UCN-01 target(s)
was involved in GSC death, we treated three GSCs lines for
each UCN-01 sensitivity group, and analyzed the levels of
total and phosphorylated PDK1 (S241), PKCa/bII (T638-41),
CDC25C (S216), and CDC2 (Y15) (Figures 3a and b and
Supplementary Figure S4a). Downmodulation of the autop-
hosphorylation site of PKCa/bII, as well as of total PKCa was
present in all GSCs only at the highest concentration tested.
Conversely, only GSC 12 among the highly sensitive lines
showed an appreciable reduction in PDK1 and its autopho-
sphorylated form, PDK1 S241 (Figures 3a and b). PDK1 was
heavily phosphorylated in the low-sensitivity line GSC1 but,
although basal levels of PDK1 S241 did not show significant
difference among GSCs from different sensitivity groups
(Figures 3a and b and Supplementary Figure S5), the ratio
between phospho- and total PDK1 was significantly higher in
the sensitive GSC lines (Supplementary Figure S4b). As
expected, because of their functional proximity to CHK1, one
of the main targets of UCN-01, the phosphorylation of
CDC25C and its downstream interactor CDC2 also exhibited
a concentration-dependent downregulation in all three
sensitivity groups (Figures 3a and b and 4 ).
In order to better understand the molecular mechanisms
underlying the differential sensitivity to UCN-01 found in
GSCs, we performed an extensive RPPM analysis on the
same three GSC lines from each group after 48 and 72 h of
treatment. Differently from TMZ, treatment with UCN-01
caused molecular changes in nearly all of the GSC lines
(Figure 4a). Interestingly, the effects of UCN-01 were not
significantly different between the time points, and although a
completely neat distinction of GSCs based on their UCN-01
sensitivity was not present in the RPPM heatmap profiles,
most low-sensitivity GSCs formed compact clusters
separated from the highly sensitive GSC lines (Figure 4a).
The medium-sensitivity group displayed intermediate mole-
cular patterns and, at the highest concentration of UCN-01,
GSCs from diverse sensitivity groups clustered much closer.
A deeper analysis made on each individual group of sensitivity
showed that clearly divergent clusters at concentrations
o1 mM are present only for the high-sensitivity GSCs
(Supplementary Figure S5a). Although a significant difference
between low/medium- and high-sensitivity GSCs was not
present in terms of caspase activation and initiation of DNA
damage response through phosphorylation of histone
H2A.Xg, cells that are highly sensitive to UCN-01 displayed
high basal pAKT S473 and pAKT T308 but low BCL2
(Figure 4b and Supplementary Figure S5b). More important,
although UCN-01 reduced pBAD S112 in all GSCs in a
concentration-dependent manner, the levels of pAKT T308,
which is the direct phosphorylation target of PDK1, rapidly and
specifically decreased only in highly sensitive GSCs. Con-
versely, the high levels of pAKT S473, which is the main
phosphorylation target of the mTORC2 complex,33 correlated
only in highly sensitive GSCs with most end points involved in
the mTOR pathway (Figure 4b). Furthermore, low- and
medium-sensitive GSCs displayed lower levels of pRPA2
S4–8, pATR S428, pCHK1 S345, and pCDC25C S216
compared with the high-sensitivity lines. RPPM data con-
firmed western blot results and, in line with this molecular
scenario, low- and medium-sensitive GSCs exhibited high
levels of pWEE1 S642 and pATM S1981, although CHK2,
which is the main effector of ATM, was more phosphorylated
in the low-sensitivity group only. Interestingly, Cyclin B1 and
Cyclin D1 were significantly elevated in highly sensitive GSCs
(Figure 4b and Supplementary Figure S5b). In order to assess
the statistical significance of the aforementioned molecular
differences between GSCs that are markedly affected by
UCN-01 compared with the others, we performed statistical
analyses (Supplementary Table S4) and produced multistate
activation maps for cell cycle or PI3K/AKT pathways that
provide an overall view of the molecular signatures of GSCs
(Supplementary Figure S6). In addition, to evaluate the
relative impact of target inhibition by UCN-01, we treated
three GSC lines, one selected from each UCN-01 sensitivity
group, with small molecule kinase inhibitors directed against
PKC, PDK1, or CHK1 and performed an in vitro drug
combination assay (Supplementary Figure S7). Inhibition of
PKC did not cause cytotoxicity, whereas simultaneous
inhibition of CHK1 (AZD7762) and PDK1 (OSU-03012) at
concentrations twofold lower than individual EC50 produced
synergistic effects on all GSCs and reproduced the sensitivity
pattern observed with UCN-01. Taken together, these data
suggest that addiction to DNA damage and PI3K/AKT/mTOR
pathways may be associated with sensitivity to UCN-01 in
GSCs.
UCN-01 significantly reduces the growth of GSC
intracerebral xenografts. Intracerebral injection of GSCs
into immunodeficient mice generates highly infiltrative tumor
xenografts that closely mimic the behavior of malignant
gliomas.22,23,34,35 Within a few weeks after grafting, the
GSCs colonize the injection site and spread toward distant
brain regions with a special tropism for the large paths of
Table 1 EC50 calculated after 72 h of treatment with UCN-01
GSC no. EC50 (lM) Sensitivity
T98G 0.003 High
12 0.043 High
15 0.090 High
5 0.094 High
14 0.184 High
13 0.221 High
10 0.242 High
11 0.367 Medium
18 0.414 Medium
7 0.548 Medium
4 0.581 Medium
6 0.628 Medium
8 0.805 Medium
9 0.949 Medium
1 1.436 Low
17 1.938 Low
U87MG 2.711 Low
16 3.416 Low
3 4269.117 Low
20 79056.358 Low
2 227826.165 Low
19 341092.047 Low
Sensitivity range: higho250 nM; 250 nMo mediumo1mM; low41 mM.
GSC lines are ordered by their sensitivity to UCN-01
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white matter. We used brain xenografts of GSCs as an
experimental paradigm to assess whether UCN-01 retains its
antitumor effect in vivo. Stable green fluorescence protein
(GFP)-expressing GSC line 1, belonging to the low-sensiti-
vity group that shows the same in vitro response to UCN-01
as the parental line (data not shown), was grafted into the
striatum of NOD-SCID mice. We coadministered UCN-01
(1mM) or vehicle (DMSO) directly with the GSC inoculation to
overcome possible problems of blood brain barrier (BBB)
penetrance. At 8 weeks after grafting, control mice (n¼ 6)
harbored tumors that invaded the homolateral striatum,
piriform cortex, corpus callosum, anterior commissure,
internal capsule, optic tract, septal nuclei, and fimbria-
hippocampus (Figure 5a), whereas the degree of brain
invasion was significantly reduced in UCN-01-treated mice
(n¼ 6, Figure 5b). The volume of the brain region invaded by
GFPþ GSCs was 10.46±0.83 and 0.78±0.19mm3
(mean±S.E.M.) in control and UCN-01-treated mice,
Figure 3 Immunoblot analysis of UCN-01 targets. (a) GSC lines selected from each sensitivity group were exposed to increasing doses of UCN-01 and the
phosphorylation levels of PKC, PDK1, CDC25C, and CDK1 (CDC2) were evaluated at 72 h. Representative blots are shown for three GSC lines (Supplementary Figure S4
displays the blots performed on the other tested GSC lines in each sensitivity group). (b) Normalized intensities of the immunoblot bands from each antibody tested are plotted
for all three GSC lines in each sensitivity group as percentage over the untreated control. No statistically significant difference between sensitivity groups at various UCN-01
concentrations was found after two-way ANOVA and Bonferroni post test
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respectively (Po0.0001, Figure 5c). In addition, treatment
with UCN-01 dramatically lowered the density of tumor cells
in the grafted striatum that scored 129.6±8.89 and
15.13±3.62 (mean±S.E.M.) cells per high-power field in
control and UCN-01-treated mice, respectively (Po0.0001,
Figure 5d). Agglomerates of autofluorescent cell debris were
observed at the brain site where UCN-01 was injected;
pathological changes of the brain parenchyma, like poroen-
cephalic cysts or glial scarring suggestive of potential UCN-
01 toxicity, were not found.
Repeated injections of UCN-01 significantly reduce the
growth of established GSC subcutaneous xenografts. In
order to evaluate the effects of repeated injections of UCN-01
on established tumor xenografts, we subcutaneously
implanted GSC 1 cells in the right flank of nude athymic
mice. When tumors reached an average diameter of
10–13mm, animals were treated with an intraperitoneal
(i.p.) injection of UCN-01 (5mg/kg in 0.15ml of saline/15%
DMSO, n¼ 5) or vehicle alone (0.15ml, n¼ 5) every other
day for 3 weeks (3 days per week, total of 9 injections).
Although it has been demonstrated that the unbound fraction
of UCN-01 in human plasma is very low because of binding
to a1-acid glycoprotein, protein binding has not been
reported in mice.36,37 After the end of the treatment cycle,
mice remained under observation for additional 3 weeks
(Figure 6a). UCN-01 was well tolerated and no signs of
toxicity were noted during the duration of the study. The
diameter of the tumors in vehicle-treated mice progressively
increased in size from 11.5±0.39 to 23.6±1.08mm
(mean±S.E.M.), whereas a marked reduction of tumor
growth rate was observed after the first UCN-01 treatment
cycle (Figure 6b). The effects of UCN-01 continued after the
second cycle of treatment and tumors had significantly
smaller diameters as compared with control animals
(13±0.55mm versus 14.8±0.37mm, mean ±S.E.M.,
P¼ 0.027). Upon cessation of UCN-01 treatment, tumors
resumed growth at a rate similar to control animals. Control
tumors displayed the typical histological pattern of GSC
xenografts22 (Figure 6c). Prominent features were extensive
areas of necrosis, arrangement of tumor cells in perinecrotic
palisades, and remarkable angiogenesis. The tumor cells
were rounded or polygonal in shape, conferring to the tumor
parenchyma an epithelioid appearance. In xenografts treated
with UCN-01, the tumor parenchyma was crossed by fibrous
septa that separated clusters of tumor cells with elongated
Figure 4 RPPM analysis on GSCs treated with UCN-01. (a) Annotated hierarchical clustering heatmaps of RPPM data obtained on nine GSCs treated with DMSO
(untreated or 0) or increasing concentrations of UCN-01. Most analytes detected are part of the DNA damage response, cell cycle, and PI3K/AKT/mTOR pathways. Data for
each GSCs represent the mean of three technical replicates. (b) Normalized intensity plots of end points extracted from the RPPM data and involved in the PI3K/AKT/mTOR,
DNA-damage response, and cell cycle pathways. Mean and SD (n¼ 3) for each sensitivity group are connected by solid, colored lines at increasing concentrations of UCN-01.
The name of the analyte and the time point are reported on top of every single plot
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morphology (Figure 6c). Fibrous healing tissue was detected
in several areas both at the center and at the periphery of
xenografts, suggesting that regressive phenomena had
occurred within the tumor. Mitotic index in this tumor was
significantly lower than in control xenografts (1.47±0.17
versus 3.09±0.37, mean ±S.E.M., Po0.002). To compare
the in vivo effect of UCN-01 systemic treatment between
low-, medium-, and high-sensitive GSCs, we chose sub-
cutaneous grafting of Matrigel implants in immunodeficient
mice that provide a well-suited model to study the early
stages of in vivo tumor growth.38 Histological examination
showed that at 4 weeks after grafting, the implants are
populated by clusters of tumor cells that strongly express
GFP on fluorescence microscopy (Supplementary Figure
S8a). Quantitative image analysis of GFP-expressing cells
revealed that UCN-01 significantly reduced tumor cell density
in the implants (Supplementary Figure S8a). Density of
fluorescent tumor cells was 19.43±0.63 (mean±S.E.M.)
and 15.63±0.69 in control and UCN-01-treated GSC line 1
xenografts, respectively (Po0.02, Student’s t-test),
26.17±1.74 and 19.60±1.22 in control and UCN-01-treated
GSC line 6 xenografts, respectively (Po0.01), and
30.19±1.58 and 11.3±1.14 in control and UCN-01-treated
GSC line 12 xenografts, respectively (Po0.001)
(Supplementary Figure S8a). Immunostaining with anti-Ki67
showed that cell proliferation was significantly lowered in
UCN-01-treated xenografts as compared with paired controls
(Supplementary Figure S8b). The proliferation index was
4.01±0.21% (mean±S.E.M.) and 2.21±0.45% in control
and UCN-01-treated GSC line 1 xenografts, respectively
(Po0.002), 5.87±0.71% and 1.93±0.36% in control and
UCN-01-treated GSC line 6 xenografts, respectively
Figure 5 Effects of UCN-01 on the growth of intracerebral GFP-expressing GSC xenografts. (a) By 8 weeks after grafting, control mice showed tumor cells in the
homolateral striatum, piriform cortex, corpus callosum, anterior commissure, internal capsule, optic tract, septal nuclei, and fimbria-hippocampus. (Left panel) Photomontage
of two adjacent coronal brain sections 240mm apart (scale bars, 1100 mm); (middle panel) schematic drawings of three adjacent sections 120mm apart showing area
demarcation for calculating tumor volume; (right panel) density of tumor cells in the grafted striatum (upper picture) and anterior commissure (lower picture) (scale bars,
140mm). (b) Brain specimen of UCN-01-treated mouse showing inhibited growth and infiltrative potential by GSCs (left panel, scale bars, 1100 mm; right panel, scale bars,
140mm). The brain area injected with UCN-01 showed autofluorescent cell debris without remarkable changes of the brain parenchyma (upper right panel). (c and d)
Diagrams showing that both the volume of the brain region invaded by the GFP-expressing GSCs and the density of these cells in the grafted striatum are significantly smaller
in UCN-01-treated mice as compared with controls (**Po0.0001)
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(Po0.001), and 4.73±1.06% and 1.07±0.28% in control
and UCN-01-treated GSC line 12 xenografts, respectively
(Po0.0001) (Supplementary Figure S8b). Overall, these
data confirmed that in vivo treatment fully reproduced the
differential response to UCN-01 observed in vitro.
Discussion
The use of concurrent and sequential TMZ is the standard
adjuvant treatment for GBM.39 In the present study, we used
patient-derived GSC lines and showed that prolonged
treatment with TMZ does not significantly impair GSC
survival that correlates with the absence of changes in many
key signaling proteins involved in GSC proliferation and
survival. TMZ is an alkylating agent and its efficacy
is dependent on MGMT promoter methylation;40 treatment
with TMZ is not curative for GBM, possibly because
of the concomitant activation of pathways other than DNA
repair. In fact, inhibitors of MEK1/2 or SRC signaling
are known to enhance CHK1 inhibitor lethality in primary
human GBM cell lines, and although the mechanism
seems to be mediated by caspases, overexpression of
Figure 6 Effects of UCN-01 treatment on established subcutaneous xenografts. (a) Subcutaneous nodules in a control and UCN-01-treated mouse by 3 weeks after the
end of treatment. (b) Growth curves of tumor xenografts in control and UCN-01-treated mice. The tumor size reached 1 week before starting UCN-01 administration (arrows) is
indicated at the time point  1. The time point 0 corresponds to the beginning of treatment. Values are expressed as means±S.E.M. *Po0.01. (c) Histological pattern of
control and UCN-01-treated tumors. Control tumors showed the typical GBM pattern with foci of necrosis, perinecrotic pseudopalisades, angiogenic phenomena, and frequent
mitotic figures (arrows). In UCN-01-treated tumors, clusters of tumor cells with elongated morphology were separated by septa of fibrous tissue. The density of tumor cells and
mitosis was much lower than in control tumors. Mitotic index was significantly lower in UCN-01-treated tumors than in controls (1.47±0.17 versus 3.09±0.37, mean
±S.E.M., Po0.002). Scale bars, 140mm (upper panels), 50mm lower panels)
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Bcl-XL alleviates but does not completely abolish MEK1/2 and
CHK1 inhibitor cytotoxicity in GBM cells.41 These findings
suggest that concomitant inhibition of multiple proliferation/
pro-survival and DNA damage/checkpoint pathways is
necessary to efficiently kill glioma cells. Indeed, GSCs display
elevated activity in multiple receptor tyrosine kinases, and the
combination of sunitinib and gefitinb as well as sunitinib and
sorafenib is effective in vitro.17
The protein signaling end points analyzed in our work are
components of the EGF-R, AKT, mTOR, MAPK, TGF-b,
WNT, and IGF-R pathways, most of which are known to be
deregulated in GBM.2 We found that preexisting activation of
a variety of signaling proteins could be related to resistance of
GSCs to TMZ treatment. Therefore, we tested the effects of a
library of 80 small molecule inhibitors on GSCs. Five
compounds passed the initial high-concentration screening
and all of them failed inmaintaining their efficacy at nanomolar
concentrations. Treatment with analog compounds showed
that, differently from all other molecules tested in this study,
UCN-01 stratifies GSCs into three main classes of sensitivity.
UCN-01 is a staurosporine derivative that is far less
promiscuous than its parent molecule, with significant activity
against a handful of kinases. In particular, UCN-01 targets
PDK1, PKC, and CHK1 (UCN-01/Staurosporine Kinome
Interaction heatmaps are available at SuperNova Life
Science, http://www.supernovalifescience.com). Pollack
et al.42–45 demonstrated significant activity of UCN-01 both
in vitro on glioma cell lines and in vivo on U87MG xenografts.
The concentrations of UCN-01 used in vitro in the cited studies
range from 20 to 200 nM that caused significant effects only on
6 out of 20 GSC lines tested in the present work. The elevated
concentration of UCN-01 needed to kill most GSCs suggests
that simultaneous inhibition of multiple kinases may be
required. Interestingly, UCN-01 efficacy does not correlate
with PKC inhibition. These data are in line with experiments
performed by others using Ro 31–8220, a staurosporine
analog that targets a panel of kinases comparable to UCN-01,
but with different potency.46 Similarly, although many positive
hits from our library screening are known to target PKC, here
we show that two selective PKC inhibitors, Go 6976 and Ro
32-0432, do not efficiently kill GSCs at submicromolar
concentrations, confirming that inhibition of PKC alone does
not induce cell death in GSCs. This hypothesis is supported by
the results of the combination assays of Ro 32-0432 with
AZD7762 or OSU-03012, specific inhibitors of CHK1 and
PDK1, respectively. In these experiments, addition of Ro 32-
0432 does not result in a significant increase in the cell death
induced by either AZD7762 or OSU-03012, whereas the
combined effects of PDK1 and CHK1 inhibition reproduce
those of UCN-01.
Our western blot data show that in most GSC lines tested,
UCN-01 treatment causes a decrease of CDC25C, CDC2,
and, at a lower extent, PKC phosphorylation but not of PDK1
phosphorylation. However, RPPM analysis of signaling down-
stream of PDK1 revealed that pAKT T308, which is the direct
phosphorylation target of PDK1, is specifically affected by
UCN-01 treatment in highly sensitive GSCs, confirming that
PDK1 auto-phosphorylation (S241) may not be a reliable
marker of the kinase activity.47 The involvement of PDK1 in
determining the different UCN-01 sensitivity of GSCswas also
suggested by a significantly higher pPDK1S241/PDK1 ratio in
highly sensitive GSC lines compared with the other two
groups. A model has been proposed for activation of PKC by
PDK1,48 and unlike its interaction with PKB/AKT, PDK1 has
been shown to activate PKC independently of PTEN and
30-phosphoinositides.49 Recently, it has been demonstrated
that PDK1 can activate PKC-i, an atypical PKC isoform with
oncogenic properties,30 and as UCN-01 binds selectively to
PDK1,29 its efficacy may be partially explained by down-
modulation of this signaling axis. The absence of activity on
GSCs displayed by all selective PKC inhibitors used in our
study and the lack of a dose-dependent decrease of PKC
phosphorylation after UCN-01 treatment might also be
explained by their selectivity against PKC-a and -b isoforms.
RPPM analysis of the PI3K/AKT/mTOR signaling pathway
revealed that GSCs with the highest sensitivity to UCN-01
display significantly elevated basal levels of pAKT S473 and,
accordingly, of all phosphoproteins interacting within the
mTOR pathway. Consistently, the presence of elevated
inhibitory AMPKa phosphorylation (S485) suggests that
sensitivity to UCN-01 is related to a preexisting activation of
pro-survival and cell growth pathways, in line with the notion
that mTOR signaling plays a critical role in cancer and, in
particular, in GBM50,51 (Supplementary Figure S7).
The observed decrease of CDC25C and CDC2 phosphor-
ylation by western blot demonstrates that, besides acting on
PDK1 and PKC, UCN-01 downregulates the activity of CHK1
and CDK1 in GSCs. It has been shown that radioresistance of
GSCs can be reversedwith specific inhibition of the CHK1 and
CHK2 checkpoint kinases, thus confirming the relevance of
DNA-damage pathways inGSC survival.9 Our RPPManalysis
of DNA-damage pathway in GSCs treated with UCN-01
confirms western blot data and shows the inhibitory phos-
phorylations of the CDC25C phosphatase and of CDC2
decrease in all GSCs in a dose-dependent manner. Moreover,
compared with the other lines, the highly sensitive GSCs
display higher basal levels of pRPA2 S4–8 and pATR S428,
indicating that CHK1 signaling has an important role in
mediating UCN-01 effects. Conversely, the presence of high
levels of activatory MDM2 and ATM phosphorylations and of
the inhibitory phosphorylation of WEE1 in the low/medium-
sensitivity group, coupled to an increased activation of the
ATM effector CHK2 only in the GSC group with the lowest
sensitivity to UCN-01, suggests that these cells may
experience less replicative stress if compared with highly
sensitive GSCs (Supplementary Figure S7).
Collectively, our RPPM data underline the importance in
GSCs of the molecular interplay between DNA damage and
PI3K/AKT/mTOR signaling cascades. These pathways,
which have been recently shown to be deranged in most
cancers and, in particular, in GBM,50,52,53 control cellular
responses to genotoxic stress and are targeted by UCN-01.
The antitumor effect of UCN-01 is confirmed in vivo in either
orthotopic or heterotopic models. In the latter, tumor growth
inhibition is maintained after three cycles of administration,
and even though after its cessation tumors started to grow at a
rate similar to untreated controls, histologic examina-
tion revealed regressive phenomena within the tumor
coupled to a significantly lower mitotic index than in control
xenografts.
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Taken together, our results show that UCN-01 efficiently
kills GSCs in vitro and in vivo, and as the concomitant
activation of multiple kinases remains a major issue in
therapeutic intervention against GBM,18–20 we suggest a
rationale for simultaneous targeting of the PDK1 and CHK1
pathways. Finally, we confirm the utility of GSCs as a
surrogate of the molecular heterogeneity of GBM and as a
proxy for individualized drug screening.
Materials and Methods
Cell culture and drugs. GSCs were obtained from primary tumors as
previously described.3,23 The O6-methylguanine-DNA methyl transferase (MGMT)
promoter methylation patterns were analyzed as previously described.23 Normal
adult neural stem cells (NS5) were obtained as previously described.27
GBM cell lines U87MG and T98G were purchased from ATCC (Manassas, VA, USA)
and were cultivated in the recommended media (see www.atcc.org for details). TMZ and
UCN-01 were purchased from Sigma (Sigma Aldrich Inc., Saint Louis, MO, USA), the
small molecule kinase inhibitor library was from Enzo Life Sciences/Biomol
(Farmingdale, NY, USA http://www.enzolifesciences.com/BML-2832/kinase-inhibitor-
library), gefitinib, sorafenib, AZD7762 and OSU-03012 were from Selleck Chemicals
(Houston, TX, USA) whereas PKC and ERK inhibitors were from Merck (Merck KGaA,
Darmstadt, Germany) and Ro 32-0432 was from Tocris Bioscience (Bristol, UK).
Reverse-phase protein microarrays. RPPMs were performed as
previously described.54 Briefly, cell lysates were diluted with 2 Tris-Glycine
SDS Sample Buffer (Life Technologies Corporation, Carlsbad, CA, USA) before
printing on nitrocellulose slides (Grace Bio-Labs, Bend, OR, USA) and were
spotted in triplicate with the Aushon 2470 contact pin arrayer (AushonBioSystems
Inc., Billerica, MA, USA), in 4-point twofold dilution curves. All antibodies used in
these experiments are listed in Supplementary Table S5.
Western blot. Cell pellets were lysed in RIPA buffer: 150 mM NaCl, 10 mM
Tris-HCl, 1 mM EDTA, and 1% Triton-X100 and Protease Inhibitor Cocktail (Sigma
Aldrich). Samples were resolved on 4–12% SDS-PAGE gels and transferred to
Hybond-C extra nitrocellulose (Amersham Pharmacia Biotech, Piscataway, NJ,
USA). Antibodies used in these experiments are listed in Supplementary Table S5.
Anti-b-actin antibody (Sigma Aldrich) was used as loading control. Quantification
of the bands was performed by using ImageJ v1.47 (National Institutes of Health,
Bethesda, MD, USA, http://imagej.nih.gov/ij/) and intensities of the bands for each
antibody tested were normalized over their correspondent actin.
Cell cycle, TUNEL, and acridine orange/propidium iodide
assays. Following mechanical dissociation, GSCs were plated in six-well
microtiter plates for cell cycle analysis and terminal deoxynucleotidyl transferase
dUTP nick-end labeling (TUNEL) assay. For acridine orange/propidium iodide (AO/
PI) staining, cells were plated in 96-well microtiter plates (Ibidi, Martinsried,
Germany). After 16 h, GSCs were treated with UCN-01 at a final concentration of
1mM, and assays were performed either at 24 or 48 h thereafter.
Intracranial implantation of GSCs and histological assessment
of tumor xenografts. Experiments involving animals were approved by the
Ethical Committee of the Catholic University School of Medicine, Rome. NOD-
SCID mice (Charles Rives, Milan, Italy) were implanted intracranially with 2 105
GFP-expressing GSCs in 5 ml of DMEM containing 1 mM UCN-01. Control mice
were injected with equal number of GSCs in 5 ml of DMEM containing vehicle only.
For grafting, the mice were anesthetized with i.p. injection of diazepam (20 mg/kg),
followed by intramuscular injection of ketamine (40 mg/kg). After 8 weeks of
survival, the mice were deeply anesthetized and transcardially perfused with 0.1 M
PBS (pH 7.4), followed by 4% PFA in 0.1 M PBS. The brain was removed, stored
in 30% sucrose buffer overnight at 41C, frozen, and serially sliced at 20mm on the
coronal plane. Sections were collected in distilled water and mounted on slides
with Vectashield mounting medium (Bio-Optica, Milan, Italy). Images were
acquired with a laser scanning confocal microscope (LSM 500 META, Zeiss,
Arese, Milan, Italy).
Subcutaneous grafting of GSCs, fluorescence microscopy,
histology, and immunohistochmistry of tumor xenografts. Nude
male athymic mice (Charles River) were implanted subcutaneously with 2 105
GSCs. For grafting, the cells were resuspended in 0.1 ml of cold PBS and the
suspension mixed with an equal volume of cold Matrigel (Becton Dickinson,
Franklin Lakes, NJ, USA). Tumor diameter was measured using a caliper and
calculated as the mean value between the shortest and the longest diameters.
Treatment with UCN-01 was initiated when the xenografts reached 10–13 mm in
mean diameter, a size at which any change can be readily detected by caliper.
UCN-01 (5 mg/kg in 0.15 ml of saline/15% DMSO) was injected i.p. once daily for 3
weeks (3 days per week; total 9 injections). UCN-01-treated mice (n¼ 5) were
maintained up to 3 weeks without any further treatment, except for measurement
of tumor mass, and then killed with an overdose of barbiturate. Controls mice
(n¼ 5) received an equal volume of saline/15% DMSO that was injected i.p. For
histologic examination of the tumors, mice were deeply anesthetized and
transcardially perfused with 0.1 M PBS (pH 7.4), followed by 4% PFA in 0.1 M
PBS. The implants were surgically removed and embedded in paraffin.
To compare the in vivo effect of UCN-01 between GSC lines belonging to low-,
medium-, and high-sensitivity groups, 2 105 GFP-expressing cells of GCSs line 1,
line 6, and line 12 were implanted subcutaneously. UCN-01 (5 mg/kg in 0.15 ml of
saline/15% DMSO) was injected i.p. once daily for 3 weeks (3 days per week; total 9
injections). Controls included mice intraperitoneally injected with an equal volume of
saline/15% DMSO. Matrigel implants were removed 4 weeks after grafting under
magnified vision, stored in 30% sucrose buffer overnight at 41C, and either
cryotomed at 20mm or embedded in paraffin and sectioned at 3 mm for evaluation of
cell density and Ki67 immunostaining, respectively.
Statistical analysis. For RPPM data analysis, unsupervised hierarchical
clustering (euclidean distance and Ward’s method of linkage) was performed on
standardized data using JMP v10.0.2 (SAS Institute, Cary, NC, USA) or ‘R’
software55 (Bioconductor56 and package ‘Heatplus’).
For in vivo data, differences in tumor volume, diameter, density of GSCs, and MI
between the UCN-01-treated and control group were evaluated using Student’s
t-test. Statistical significance was assigned to P-values ofo0.05.
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